ACTIV-4b is a national study to determine if taking an FDA-approved and commonly prescribed blood thinner Eliquis (apixaban), or alternatively, taking baby aspirin is better than taking no blood thinner to prevent blood clots in people with COVID-19 who are recovering from their symptoms at home.
By participating in this study, you will help us learn more about COVID-19 and the best way to treat people newly diagnosed with COVID-19.
The chance of blood clots in patients who are diagnosed with COVID-19 is higher than for patients who do not have COVID-19.
To date, doctors can use blood thinner medicines or aspirin to lower the risk of blood clots forming in veins and arteries. Blood clots that form inside the big blood vessels of the legs can travel through the body to the lungs, called pulmonary embolus, which can make it hard to get oxygen.
With COVID-19, blood clots can also form directly in the lungs or in the heart and brain. Blood thinners can be given in different doses to prevent blood clots from forming. Doctors often use lower doses to prevent blood clots from happening and higher doses to treat blood clots that have already happened.
The study team will call you to confirm that you received your package and to answer any questions you may have.
After 75 days the study team will make one additional phone call to check-in and see how you're doing.
The ACTIV-4b study is comparing preventative treatments to see if taking an FDA approved and commonly prescribed blood thinner Eliquis (apixaban), or alternatively, taking baby aspirin is better than taking no blood thinner to prevent blood clots in people with COVID-19 who are recovering from their symptoms at home.
Doctors and researchers know these medications work well to prevent blood clots already, but the ACTIV-4b study hopes to find which particular dosage and medication does that best for patients with COVID-19.
You would be randomly assigned by a computer (like flipping a coin) to one of four groups:
Principal Investigator, Data Coordinating Center
Principal Investigator
Trial Chairman
Principal Investigator, Research Communication Center Director
Principal Investigator, Data Coordinating Center
Principal Investigator
Trial Chairman
Principal Investigator, Research Communication Center Director